These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11734817)

  • 1. Goliath befriends David.
    Clarke T; Pearson H
    Nature; 2001 Nov; 414(6863):482-3. PubMed ID: 11734817
    [No Abstract]   [Full Text] [Related]  

  • 2. Bigger isn't always better.
    Nature; 2002 Jul; 418(6896):353. PubMed ID: 12140518
    [No Abstract]   [Full Text] [Related]  

  • 3. Sanofi takeover jeopardizes Aventis biotech deals.
    Mitchell P
    Nat Biotechnol; 2004 Jun; 22(6):639-40. PubMed ID: 15175667
    [No Abstract]   [Full Text] [Related]  

  • 4. Concerns raised over declining antiinfectives R&D.
    Fox JL
    Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
    [No Abstract]   [Full Text] [Related]  

  • 5. Back to the future.
    Offit P
    Expert Rev Vaccines; 2004 Apr; 3(2):107-8. PubMed ID: 15056035
    [No Abstract]   [Full Text] [Related]  

  • 6. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098
    [No Abstract]   [Full Text] [Related]  

  • 7. An audience with … Wolfgang Plischke.
    Plischke W; Mullard A
    Nat Rev Drug Discov; 2014 Apr; 13(4):252. PubMed ID: 24687059
    [No Abstract]   [Full Text] [Related]  

  • 8. Increase in R&D openness to tackle disease in the developing world.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
    [No Abstract]   [Full Text] [Related]  

  • 9. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Massachusetts: Mass effect.
    Savage N
    Nature; 2016 Sep; 537(7618):S18-9. PubMed ID: 27580137
    [No Abstract]   [Full Text] [Related]  

  • 11. Deal watch: Ablynx and Merck Serono collaborate on next-generation antibody products.
    Nat Rev Drug Discov; 2008 Nov; 7(11):881. PubMed ID: 18974745
    [No Abstract]   [Full Text] [Related]  

  • 12. Reproducibility: Team up with industry.
    Edwards A
    Nature; 2016 Mar; 531(7594):299-301. PubMed ID: 26983524
    [No Abstract]   [Full Text] [Related]  

  • 13. David versus Goliath.
    Check E; Castellani F
    Nature; 2004 Dec; 432(7017):546-8. PubMed ID: 15577877
    [No Abstract]   [Full Text] [Related]  

  • 14. Patient heal thyself.
    Benson RS
    Drug Discov Today; 2005 Feb; 10(3):159-61. PubMed ID: 15708524
    [No Abstract]   [Full Text] [Related]  

  • 15. Centers for education and research in therapeutics.
    Woosley RL
    Clin Pharmacol Ther; 1994 Mar; 55(3):249-55. PubMed ID: 8143390
    [No Abstract]   [Full Text] [Related]  

  • 16. Will R&D make Merck hot again?
    Simons J
    Fortune; 2002 Jul; 146(1):89-90, 92, 94. PubMed ID: 12119729
    [No Abstract]   [Full Text] [Related]  

  • 17. Daniel Vasella.
    Hughes B
    Nat Rev Drug Discov; 2010 Feb; 9(2):98. PubMed ID: 20118958
    [No Abstract]   [Full Text] [Related]  

  • 18. Bioanalytical outsourcing: transitioning from Pharma to CRO.
    Hayes R
    Bioanalysis; 2017 Aug; 9(15):1149-1152. PubMed ID: 28763257
    [No Abstract]   [Full Text] [Related]  

  • 19. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. $1 billion R&D spender emerges.
    Ward M
    Nature; 1995 Aug; 376(6542):626. PubMed ID: 7651500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.